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Background: Both BRCA1 and angiotensin II type 1 receptor (AGTR1) play a critical role in ovarian cancer
progression. However, the crosstalk between BRCA1 and AGTR1 signaling pathways remains largely unknown.
Methods: BRCA1 promoter methylation was analyzed by bisulfite sequence using primers focused on the core
promoter region. Expression levels of BRCA1 and AGTR1 were assessed by immunohistochemistry and real-time PCR.
Regression analysis was used to examine the possible relationship between BRCA1 and AGTR1 protein levels. Knockdown
or overexpression of BRCA1 was achieved by using a lentiviral vector in 293 T cells and SKOV3 ovarian carcinoma cells,
and primary non-mutated and BRCA1-mutated ovarian cancer cells.
Results: BRCA1 dysfunction (BRCA1 mutation or hypermethylated BRCA1 promoter) ovarian cancer showed decreased
AGTR1 levels compared to normal tissue. In contrast, AGTR1 expression was increased in non-BRCA1-mutated ovarian
cancer. Notably, BRCA1 activation was an effective way to induce AGTR1 expression in primary ovarian cancer cells and a
positive correlation exists between BRCA1 and AGTR1 expression in human ovarian cancer specimens.
Conclusions: These results indicate that BRCA1 may be a potential trigger involved in the transcriptional regulation of
AGTR1 in the development of ovarian cancer.
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Ovarian cancer is the most lethal gynecological malig-
nancy in women worldwide [1]. To date, although the
exact cause of ovarian cancer remains largely unknown,
BRCA mutations are the main known hereditary factor
[2], and the risk of ovarian cancer conferred by BRCA
mutations can be regulated by both genetic and environ-
mental components [3]. The angiotensin II type 1 receptor
(AGTR1) is a novel component of the renin-angiotensin
system, and has a direct effect on blood pressure and heart
hypertrophy [4]. Recently, AGTR1 has drawn considerable
interest, not only in the field of cardiovascular risk but also
in several types of gynecological malignancies, such as
endometrial cancer [5,6], cervical carcinoma [7], and espe-
cially ovarian cancer [8-10]. Accumulating evidence also* Correspondence: leeda@ymail.com; yangq@sj-hospital.org
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stated.indicates that an increased risk of ovarian cancer and poor
patient outcome are associated with AGTR1 expression
[9,11]. Our previous study has found that AGTR1 interacts
with genetic and environmental factors, which exert a
potent effect on the proliferation and survival of the
estrogen-induced Ishikawa cell line [12]. Several recent
studies also support a possible role for AGTR1 in regu-
lating cell proliferation during cancer development [13].
Additionally, an increasing amount of evidence suggests
that BRCA1 haploinsufficiency mutations are more likely
to result in cancer, due to an extraordinary ability for
clonal growth and proliferation [14]. However, the com-
plex interrelationship between AGTR1 and BRCA1 re-
mains to be elucidated. Therefore, the present study was
undertaken to investigate AGTR1 expression from genetic
(BRCA1 mutated or not) and epigenetic (BRCA1 pro-
moter methylated or not) aspects in ovarian cancer, and to
provide novel insights into the regulatory mechanism of
AGTR1.his is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
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Patients and tissue collection
This study was approved by the Institutional Review Board
at China Medical University. Serous ovarian cancer pa-
tients were enrolled between 2010 and 2012, and all
patients gave informed consent. Fresh tumor samples, ad-
jacent normal ovarian tissues, ascites and blood samples
were obtained at the time of primary surgery before any
chemotherapy or radiotherapy. Hematoxylin and eosin
staining of the samples for histopathological diagnosis and
grading were determined by three staff pathologists using
the World Health Organization criteria. All patients were
screened for BRCA1 mutations by multiplex polymerase
chain reaction (PCR) with complete sequence analysis
using methods reported by Bi and Simard [15,16], Their
characteristics are given in Additional file 1: Table S1.
Cell culture and lentiviral transfection
Primary ovarian cancer cells were obtained from ascites for
15 BRCA1-mutated and 15 non-mutated patients undergo-
ing surgery for ovarian cancer and cultured in RPMI 1640
with 10% fetal bovine serum (Invitrogen, CA USA) using
methods reported by Szlosarek [17]. Primary ovarian cancer
cells used in all experiments were passage 2. The prolifera-
tion rate is shown in Additional file 2: Figure S1 (methods
shown in Additional file 3). Human 293 T cells and SKOV3
ovarian carcinoma cells were maintained in DMEM with
10% fetal bovine serum (Invitrogen). Each experiment was
repeated four times for primary ovarian cancer cells of each
patient, 293 T cells and SKOV3 cells. Lentiviral vectors ex-
pressing short hairpin RNAs (shRNAs) against BRCA1
(NM_007299) were obtained from GeneChem Co., Ltd
(Shanghai, China), and synthesized as follows: Forward: 5′-
CCGGAACCTGTCTCCACAAAGTGTGCTCGAGCACA
CTTTGT GGAGACAGGTTTTTTTG-3′, and Reverse:
5′-AATTCAAAAAAACCTGTCTCCACAAAGTGTGCT
CGAGCACACTTTGTGGAGACAGGTT-3′. The non-
silencing siRNA sequence (TTCTCCGAACGTGTCACGT)
was used as a negative control. For overexpression of
BRCA1, the open reading frame of BRCA1 (NM_007299)
was cloned into the lentiviral vector GV287 (Ubi-
MCS-3FLAG-SV40-EGFP) (GeneChem, Shanghai, China).
Transfections were performed using polybrene and en-
hanced infection solution (GeneChem) according to the
manufacturer’s recommended protocol. The efficiency
of BRCA1 knockdown and overexpression is shown in
Additional file 4: Figure S2 (methods shown in Additional
file 3).
Real-time quantitative PCR
Total RNA was extracted using Trizol reagents (Invitro-
gen) according to the manufacturer’s protocol. DNA
contamination was removed by adding DNase I (Invitro-
gen) according to the manufacturer’s protocols. TotalRNA was then reverse-transcribed from 2 μg of RNA using
the PrimeScript RT Master Mix kit (TaKaRa, Dalian,
China) and amplified by SYBR Premix Ex TaqTM II
(TaKaRa) in a Roche LightCycler 2.0 instrument (Roche
Diagnostics, Mannheim, Germany). The specific primer se-
quences were as follows: AGTR1: 5′-CCTCAGATAATG-
TAAGCTCATCCAC-3′ (F) and 5′-GCTGCAGAGGAAT
GTTCTCTT-3′ (R); BRCA1: 5′-GGCTATCCTCTCAG
AGTGACATTT-3′ (F) and 5′-GCTTTATCAGGTTATGT
TGCATGG-3′ (R); GAPDH: 5′-AGGTGAAGGTCGGA
GTCA-3′ (F) and 5′-GGTCATTGATGGCAACAA-3′(R).
GAPDH mRNA was amplified as an internal control
for normalization of each sample. All samples were ana-
lyzed in triplicate using the 2–ΔΔCT method.
Immunohistochemistry
The standard SP kit (Zhongshan, Beijing, China) was used
for immunohistochemical staining. Briefly, serial 4-μm
sections were obtained from each paraffin-embedded tis-
sue block. Following deparaffinization and rehydration,
sections were subjected to microwave antigen retrieval.
The primary antibody were rabbit polyclonal anti-AGTR1
(sc-1173) (1:100; Santa, Cruz Biotechnologies, USA) and
rabbit polyclonal anti-BRCA1 (sc-642) (1:100; Santa), and
the sections were incubated overnight at 4°C with this
antibody. 3,3‘-diaminobenzidine was used as the chromo-
gen. Nuclei were counterstained with hematoxylin, and
slides were dried and mounted. Negative controls were in-
cubated with phosphate-buffered saline instead of the
antibody. Immunostaining was evaluated by two inde-
pendent pathologists, blinded to the identity of subject
groups. Area quantification was made with a light micro-
scope at a magnification of 400 × and analyzed by Image-
Pro Plus 6.0 (Media 2 Cybernetics, USA). Intensity of the
staining was divided into 10 units.
Bisulfite sequencing for BRCA1 promoter
All the tissues were used for bisulfite sequencing from the
non-BRCA1-mutated cases. Genomic DNA extracted from
ovarian cancer and normal ovarian tissue with a TIANamp
Genomic DNA kit (Tiangen biotech, Beijing, China) was
subjected to bisulfite conversion using the EZ DNA
Methylation-Direct kit (Zymo research, Orange, USA) fol-
lowing the manufacturer’s instructions; the conversion effi-
ciency was estimated to be at least 99.6%. It was then
amplified by nested PCR. After gel purification, cloning
and transformation into E. coli Competent Cells JM109
(TaKaRa), ten positive clones of each sample were se-
quenced to ascertain the methylation patterns of each CpG
locus. The following primers were used for BRCA1 gene
(Accession number: NG_005905; GRCh37/hg19) pro-
moter: round I, F: 5′-TTGTAGTTTTTTTAAAGAGT-3′
and R: 5′-TACTACCTTTACCCAAAACAAAA-3′; and
round II, F: 5′-GTAGTTTTTTTAAAGAGTTGTA-3′ and
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Figure 1 Effects of BRCA1 on AGTR1 expression. A-D, relative AGTR1 mRNA levels after overexpression or knockdown of BRCA1 in 293 T cells,
human SKOV3 ovarian carcinoma cells, and primary non-mutated and BRCA1-mutated ovarian cancer cells. Bar graphs show mean ± SD. Sh,
shRNAs; Op, overexpression.
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Figure 2 AGTR1 expression patterns in BRCA1-mutated and non-mutated ovarian cancer. A and C, relative AGTR1 mRNA levels were
measured in non-mutated or BRCA1-mutated ovarian cancer compared to their adjacent normal tissue, respectively (each group, n = 15). Bi and
Di, sections were subjected to immunostaining for AGTR1 in non-mutated or BRCA1-mutated ovarian cancer compared to their adjacent normal
tissue, respectively (each group, n = 15). Arrow shows positive staining for AGTR1 in the membrane. Bii and Dii, summary of the percentages of
AGTR1-positive cells from the measurements shown in Bi and Di, respectively. Intensity of the staining was divided into 10 units. Magnification is 400 ×.
Bi et al. Journal of Ovarian Research 2013, 6:89 Page 3 of 7
http://www.ovarianresearch.com/content/6/1/89
Bi et al. Journal of Ovarian Research 2013, 6:89 Page 4 of 7
http://www.ovarianresearch.com/content/6/1/89R: 5′-ACCTTTACCCAAAACAAAAA-3′. The conditions
were as follows: 95°C for 2 min, 40 cycles of 30s at 95°C,
30s at 56°C and 45 s at 72°C, then 72°C for 7 min.Statistical analysis
Regression analysis was used to examine the possible rela-
tionship between AGTR1 and BRCA1 expression. The data
are presented as means ± SD. Statistical differences in the
data were evaluated by Student’s t test or one-way ANOVA
as appropriate, and were considered significant at P < 0.05.13.3 p13.1 17p12 17p11.2 q11.2 1
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BRCA1 can regulate AGTR1 expression in primary ovarian
cancer cells
To confirm the role of BRCA1 in the regulation of
AGTR1, the effects of overexpression or knockdown of
BRCA1 were observed in 293 T cells, human ovarian car-
cinoma cell line SKOV3, primary ovarian cancer cells with
identified BRCA1 mutations or non-mutation. The results
indicated that there were no significant changes in the ex-
pression of AGTR1 after overexpression or knockdown
of BRCA1 in 293 T and SKOV3 cells (Figure 1A-B).7q12 17q22 24.3 25.1 q25.3
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http://www.ovarianresearch.com/content/6/1/89Interestingly, we observed that overexpression of BRCA1
was an effective way to induce an increase in AGTR1
levels in primary non-mutated and BRCA1-mutated ovar-
ian cancer cells, although AGTR1 levels were not sensitive
to the BRCA1 knockdown (Figure 1C-D).
Differences in expression patterns of AGTR1 in BRCA1-
mutated and non-mutated ovarian cancer
Real-time PCR and immunohistochemical analysis showed
that the levels of AGTR1 mRNA and protein were in-
creased in non-BRCA1-mutated ovarian cancer compared
to adjacent normal tissue (Figure 2A and B, P < 0.05). It is,
however, interesting to note that BRCA1-mutated ovarian
cancer as compared to their adjacent normal tissue reduced
the expression of AGTR1 (Figure 2C and D, P < 0.05).
Hypermethylated BRCA1 promoter-mediated decreased
expression of BRCA1 is correlated with AGTR1 levels
In mammals, promoter methylation at CpG dinucleotides
is an important feature regulating gene expression [18].
Consistent with this idea, we showed that ovarian cancer
tissue with a hypermethylated BRCA1 promoter displayed
decreased expression of BRCA1 in comparison with adja-
cent normal tissue (Figure 3Aii and Bi, P < 0.05). However,
no significant BRCA1 expression differences were ob-
served in ovarian cancer with unmethylated BRCA1 pro-
moter as compared to adjacent normal tissue (Figure 3Aiii
and Ci, P > 0.05). Based on these considerations, the low0 2 4 6 8 10
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Figure 4 Correlation between the expression levels of BRCA1 and AG
and AGTR1 protein levels in 63 human ovarian cancer tissue samples. Inten
immunohistochemical staining showing the positive correlation between t
Magnification is 400 ×.levels of BRCA1 appeared to be mediated by promoter
hypermethylation, making this an appropriate model to in-
vestigate the physiological relationship between BRCA1
and AGTR1. Notably, the expression levels of AGTR1 were
decreased markedly (Figure 3Biii), along with hyperme-
thylated promoter-mediated BRCA1 deficiency in ovarian
cancer (Figure 3Bii). In contrast, AGTR1 expression was
increased in ovarian cancer tissue (Figure 3Ciii), along
with no significant difference of BRCA1 promoter methy-
lation and expression (Figure 3Ci and Cii).
AGTR1 is positively correlated with BRCA1 expression in
ovarian cancer samples
Of particular interest and potential clinical relevance,
the relationship between BRCA1 and AGTR1 expression
was studied in 63 human ovarian cancer specimens. Our
results showed that there is a significant positive associ-
ation between BRCA1 and AGTR1 protein expression
(Figure 4A and B).
Discussion
In this study, we report for the first time an association be-
tween BRCA1 and AGTR1 status in ovarian cancer: (i)
AGTR1 expression was increased in non-BRCA1-mutated
ovarian cancer, but BRCA1 dysfunction (such as via
BRCA1 mutation or promoter hypermethylation) was asso-
ciated with decreased AGTR1 levels; (ii) there was a positive
correlation between BRCA1 and AGTR1 expression inBRCA1 AGTR1
TR1 in ovarian cancer samples. A, Correlation between the BRCA1
sity of staining was divided into 10 units. B, Examples of
he expression levels of BRCA1 and AGTR1 in ovarian cancers.
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effective at inducing AGTR1 expression in primary ovarian
cancer cells. These results suggest that BRCA1 may be a
potential trigger for AGTR1. Interestingly, the activation ef-
fects of BRCA1 were primarily observed in cells originating
from primary ovarian cancer, especially BRCA1-mutated
ovarian cancer cells, but 293 T and SKOV3 cells were in-
sensitive to the overexpression or knockdown of BRCA1.
Accordingly, a specific intracellular environment may exist,
and AGTR1 expression is likely to be the long-term result
of a complex interaction of multiple factors in BRCA1-
related ovarian cancer. Notably, a body of evidence suggests
that there is extensive crosstalk among BRCA1 signaling
pathways and hormone receptors. For example, the insulin-
like growth factor 1 receptor (IGF1R) gene is a downstream
target for BRCA1, as wild-type BRCA1 expression sup-
presses promoter activity and endogenous IGF1R levels [3];
BRCA1 can lead to degradation of the progesterone recep-
tor by counteracting the action of progesterone; multiple
mechanisms are involved in BRCA1-mediated estrogen
receptor repression [19,20]. However, to date, there have
been few reports about the interactions between BRCA1
and AGTR1. Moreover, mounting evidence indicates that
BRCA1 tumor suppressor gene dysfunction has an im-
portant role in promoting cell proliferation and survival
[14,21-23]. The mechanism may involve: 1) inducing
insulin-like growth factor 1 expression [3,24] in an estrogen
receptor α-dependent manner [24,25]; and 2) stimulating
progesterone receptor activity by facilitating progesterone
binding to the progesterone response elements [26].
AGTR1 also plays a key role in regulating cell growth
and proliferation during the initiation and progression of
cancer [27,28]. Therefore, the discovery of BRCA1-medi-
ated AGTR1 expression will stimulate new interest in the
study of BRCA1-related cellular proliferation, although the
details remain unclear. To date, it is not fully understood
how BRCA1 activates AGTR1 gene expression at the mo-
lecular level. However, some insight may be gained by
further study, and preliminary data suggest that a direct
interaction between miR-155 and AGTR1 (Additional file 5:
Figure S3, methods shown in Additional file 3). Specifically,
miR-155 is a regulatory target for BRCA1 [29,30]; BRCA1
knockdown results in a two- to three-fold increase in miR-
155 levels [29,31], which may be involved in AGTR1 tran-
scriptional repression, but there are still some details that
need to be considered.
Conclusion
Our results indicate that BRCA1 may be a potential regu-
lator of AGTR1 in ovarian cancer cells. Based on these
findings, there are some interesting issues that need to be
considered in future studies, such as how BRCA1 affects
AGTR1 transcription and whether other factors could co-
operate with BRCA1 in controlling AGTR1 expression.Also, the complex interactions between BRCA1 and
AGTR1 signaling pathways need to be clarified. All of this
may improve our understanding of the basic molecular
mechanism of BRCA1-related ovarian cancer.
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Additional file 2: Figure S1. Cell proliferation rate of primary ovarian
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Additional file 4: Figure S2. The efficiency of BRCA1 knockdown and
overexpression.
Additional file 5: Figure S3. The interaction between miR-155 and
AGTR1.
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